ReviewCurrent neuropharmacology2021
Pharmacologic Treatment of Restless Legs Syndrome.
Review in Current neuropharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Restless legs syndrome as a comorbidity in amyotrophic lateral sclerosis: a systematic review and meta-analysis.BMC neurology · 2025Pooled it
- Current perspectives and trends in acupuncture for sleep disorders: a bibliometric analysis.Frontiers in psychiatry · 2024Pooled it
- Improvement of restless leg syndrome in maintenance hemodialysis patients with limb ischemic preconditioning: a single-center randomized controlled clinical trial.Renal failure · 2023Trial
- The evolving treatment landscape of restless legs syndrome.Therapeutic advances in neurological disorders · 2026Review
- Sleep disorders in stroke rehabilitation: mechanisms, impacts, and multidisciplinary management - a narrative review.Frontiers in neurology · 2026Review
- Prerequisites for self-care actions in individuals with restless legs syndrome-A deductive qualitative analysis based on the COM-B model.Journal of health psychology · 2025Article
- Integrative sleep management: from molecular pathways to conventional and herbal treatments.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Validation of the eHealth Literacy Scale Instrument in a Restless Legs Syndrome Population: Classical Test Theory and Rasch Analysis Study.Journal of medical Internet research · 2025Article
- Fresh Genetic Insights Into Micronutrients Influences on Restless Legs Syndrome Risk.Food science & nutrition · 2025Article
- Restless Legs Syndrome in Adult Primary Care.Cureus · 2025Review
- Experiences of facilitators and barriers for fulfilment of human needs when living with restless legs syndrome: a qualitative study.International journal of qualitative studies on health and well-being · 2024Article
- The ethos brief index-validation of a brief questionnaire to evaluate wellness based on a holistic perspective in patients with restless legs syndrome.Sleep & breathing = Schlaf & Atmung · 2024Article
- The psychometric properties of the Pearlin Mastery Scale in persons living with restless legs syndrome.PloS one · 2024Article
- Alterations of the thalamic nuclei volumes and intrinsic thalamic network in patients with restless legs syndrome.Scientific reports · 2023Article
- Article
- Olanzapine-induced restless leg syndrome (Willis-Ekbom disease): A case report.SAGE open medical case reports · 2022Article
- Investigating the inflammation marker neutrophil-to-lymphocyte ratio in Danish blood donors with restless legs syndrome.PloS one · 2021Article
- Pharmacological and Non-pharmacological Treatments of Sleep Disorders in Parkinson's Disease.Current neuropharmacology · 2021Review
- Restless legs syndrome and growing pains in childhood: understanding the link.Frontiers in neurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Restless legs syndrome (RLS)/Willis-Ekbom disease is a neurologic disorder characterized by a strong desire to move when at rest (usually in the evening) and paraesthesia in their lower legs. The most widely used therapies for first-line treatment of RLS are dopaminergic drugs; however, their long-term use can lead to augmentation. α2δ Ligands, opioids, iron, glutamatergic drugs, adenosine, and sleep aids have been investigated as alternatives. The pathogenesis of RLS is not well understood. Despite the efficacy of dopaminergic drugs in the treatment of this disorder, unlike in Parkinson's disease dopaminergic cell loss in the substantia nigra has not been observed in RLS. The etiology of RLS is likely complex, involving multiple neural pathways. RLS-related genes identified in genome-wide association studies can provide insight into the mechanistic basis and pathophysiology of RLS. Here we review the current treatments and knowledge of the mechanisms underlying RLS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.